CEO Prateek Singh invented the core tech at VTT, Finland's top research center, and holds multiple patent families in microfluidics. COO Harri Hallila built medtech startup Synoste and sold it to Globus Medical for $23.5M. ETH Zurich-trained, exited, and back for round two.

Their platform replaces enzyme-based immunoassays with a physics-based magnetic cycling mechanism that reads a single protein molecule over and over - amplifying signal without adding noise. Up to 1,000× more sensitive than today's gold standard, from a few drops of blood.

Cancer survival rates exceed 90% when caught early. Alzheimer's slows dramatically with early intervention. Yet current diagnostics can't see molecular warning signals until symptoms appear. Proteins.1 makes the invisible measurable, years earlier than today.

Launched this month with a €4.7M pre-seed led by Lifeline Ventures and Cloudberry Ventures, plus backing from VTT and Business Finland. US and Finnish patents granted. Starting in oncology, neurology, and immunology - clinical diagnostics next.